Buy QNTM by Nov 12, 2026.

On August 14, 2026, Quantum BioPharma Ltd. filed a Form 6-K with the SEC, providing its financial and operational results for the second quarter ended June 30, 2026. The company reported a strengthened balance sheet, with combined cash, cash equivalents, and digital assets totaling approximately US$9.5 million, up from US$4.1 million at the end of 2025. Specifically, cash and cash equivalents nearly doubled to US$3.65 million. Management noted a disciplined reduction in costs, with total operating expenses falling 53% year-over-year …